Philadelphia, PA – According to filings with the U.S. Securities and Exchange Commission, Passage BIO is raising $110,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Operating Officer, Jill Quigley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Passage BIO

Passage Bio is a fully integrated genetic medicines company based in Philadelphia, PA that is developing a portfolio of six life transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company was founded by industry veterans Stephen Squinto, Ph.D., and Tachi Yamada, M.D., in a partnership with gene therapy pioneer James Wilson, M.D., Ph.D. The company has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program as well as the Penn Orphan Disease Center.

To learn more about Passage BIO, visit http://www.passagebio.com/

Contact:
Jill Quigley, Chief Operating Officer
https://www.linkedin.com/in/jill-thompson-quigley-5862816/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved